95 related articles for article (PubMed ID: 30348714)
1. Radiological Features of Programmed Cell Death-Ligand 2-positive Lung Adenocarcinoma: A Single-institution Retrospective Study.
Takada K; Toyokawa G; Azuma K; Takamori S; Jogo T; Hirai F; Tagawa T; Kawahara A; Akiba J; Okamoto I; Nakanishi Y; Oda Y; Hoshino T; Maehara Y
In Vivo; 2018; 32(6):1541-1550. PubMed ID: 30348714
[TBL] [Abstract][Full Text] [Related]
2. Factors correlating the expression of PD-L1.
Lu F; Wang E; Liu H
BMC Cancer; 2024 May; 24(1):642. PubMed ID: 38796458
[TBL] [Abstract][Full Text] [Related]
3. Texture Features of
Norikane T; Ishimura M; Mitamura K; Yamamoto Y; Arai-Okuda H; Manabe Y; Murao M; Morita R; Obata T; Tanaka K; Murota M; Kanaji N; Nishiyama Y
J Clin Med; 2024 Mar; 13(6):. PubMed ID: 38541851
[No Abstract] [Full Text] [Related]
4.
Cytryn SL; Pandit-Taskar N; Lumish MA; Maron SB; Gu P; Ku GY; Chou JF; Capanu M; Antoine A; Loegel D; Feder L; Philemond S; Lyashchenko SK; Lewis JS; Paroder V; Srivastava A; Tang LH; Schoder H; Janjigian YY
J Nucl Med; 2024 May; 65(5):722-727. PubMed ID: 38514081
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors of resected pathological stage I lung adenocarcinoma: evaluating subtypes and PD-L1/CD155 expression.
Nishizawa N; Shimajiri S; Oyama R; Manabe T; Nemoto Y; Matsumiya H; Honda Y; Taira A; Takenaka M; Kuroda K; Tanaka F
Sci Rep; 2023 Dec; 13(1):21687. PubMed ID: 38065981
[TBL] [Abstract][Full Text] [Related]
6. Heterogeneity of PD-L1 expression between invasive and lepidic components of lung adenocarcinomas.
Hazim A; Majithia N; Murphy SJ; Wigle D; Aubry MC; Mansfield AS
Cancer Immunol Immunother; 2021 Sep; 70(9):2651-2656. PubMed ID: 33599823
[TBL] [Abstract][Full Text] [Related]
7. Deciphering Cholesterol's Role in PD-L2 Stability: A Distinct Regulatory Mechanism From PD-L1.
Zhang Y; Xiao T; Wen M; Shen L; Du L; Wei S; Wu B; Yu Y; Wang S; OuYang B
J Mol Biol; 2024 Apr; 436(8):168500. PubMed ID: 38401626
[TBL] [Abstract][Full Text] [Related]
8. The prognostic significance of PD-1 and its ligands in non-small cell lung cancer.
Usluer O; Gökbayrak ÖE; Erol A; Aktaş TÇ; Batıhan G; Örs Kaya Ş; Üçvet A; Aydoğdu Z; Altun Z; Öztop İ; Aktaş S
Turk Gogus Kalp Damar Cerrahisi Derg; 2024 Jan; 32(1):84-92. PubMed ID: 38545362
[TBL] [Abstract][Full Text] [Related]
9. The role of radiotherapy in tumor immunity and the potential of PET/CT in detecting the expression of PD-1/PD-L1.
Shen LF; Fu ZM; Zhou SH
Jpn J Radiol; 2024 Apr; 42(4):347-353. PubMed ID: 37953364
[TBL] [Abstract][Full Text] [Related]
10. Adaptive selection in the evolution of programmed cell death-1 and its ligands in vertebrates.
Ahmad HI; Zhou J; Ahmad MJ; Afzal G; Jiang H; Zhang X; Elokil AA; Khan MA; Li L; Li H; Ping L; Chen J
Aging (Albany NY); 2020 Feb; 12(4):3516-3557. PubMed ID: 32045365
[TBL] [Abstract][Full Text] [Related]
11. Programmed cell death-ligand 2: new insights in cancer.
Yang Y; Yan X; Bai X; Yang J; Song J
Front Immunol; 2024; 15():1359532. PubMed ID: 38605944
[TBL] [Abstract][Full Text] [Related]
12. Association between programmed death-1 pathway and major depression.
Huang KW; Huang TL
World J Biol Psychiatry; 2023 Nov; 24(9):822-828. PubMed ID: 37139744
[TBL] [Abstract][Full Text] [Related]
13. Intrapleural perfusion hyperthermia improves the efficiency of anti‑PD1 antibody‑based therapy for lung adenocarcinoma: A case report.
Wang X; Song J; Hu L; Ren G; Geng N; Song Z
Oncol Lett; 2024 May; 27(5):217. PubMed ID: 38586203
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory functions of PD-L1 and PD-L2 in the regulation of anti-tumor immunity in murine tumor microenvironment.
Umezu D; Okada N; Sakoda Y; Adachi K; Ojima T; Yamaue H; Eto M; Tamada K
Cancer Immunol Immunother; 2019 Feb; 68(2):201-211. PubMed ID: 30357491
[TBL] [Abstract][Full Text] [Related]
15. Pseudoprogression in Previously Treated Patients with Non-Small Cell Lung Cancer Who Received Nivolumab Monotherapy.
Fujimoto D; Yoshioka H; Kataoka Y; Morimoto T; Hata T; Kim YH; Tomii K; Ishida T; Hirabayashi M; Hara S; Ishitoko M; Fukuda Y; Hwang MH; Sakai N; Fukui M; Nakaji H; Morita M; Mio T; Yasuda T; Sugita T; Hirai T
J Thorac Oncol; 2019 Mar; 14(3):468-474. PubMed ID: 30468872
[TBL] [Abstract][Full Text] [Related]
16. Differences in PD-L1 expression on tumor and immune cells between lung metastases and corresponding primary tumors.
Takamori S; Takada K; Tagawa T; Toyokawa G; Hirai F; Yamashita N; Okamoto T; Oki E; Yoshizumi T; Oda Y; Maehara Y
Surg Oncol; 2018 Dec; 27(4):637-641. PubMed ID: 30449485
[TBL] [Abstract][Full Text] [Related]
17. A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade.
Jerby-Arnon L; Shah P; Cuoco MS; Rodman C; Su MJ; Melms JC; Leeson R; Kanodia A; Mei S; Lin JR; Wang S; Rabasha B; Liu D; Zhang G; Margolais C; Ashenberg O; Ott PA; Buchbinder EI; Haq R; Hodi FS; Boland GM; Sullivan RJ; Frederick DT; Miao B; Moll T; Flaherty KT; Herlyn M; Jenkins RW; Thummalapalli R; Kowalczyk MS; Cañadas I; Schilling B; Cartwright ANR; Luoma AM; Malu S; Hwu P; Bernatchez C; Forget MA; Barbie DA; Shalek AK; Tirosh I; Sorger PK; Wucherpfennig K; Van Allen EM; Schadendorf D; Johnson BE; Rotem A; Rozenblatt-Rosen O; Garraway LA; Yoon CH; Izar B; Regev A
Cell; 2018 Nov; 175(4):984-997.e24. PubMed ID: 30388455
[TBL] [Abstract][Full Text] [Related]
18. Making cytology specimens solid materials for testing predictive marker of immunotherapy in NSCLC.
Wang H; Spatz A
Oncotarget; 2018 Oct; 9(84):35472-35473. PubMed ID: 30464800
[No Abstract] [Full Text] [Related]
19. A potential mechanism of the onset of acute eosinophilic pneumonia triggered by an anti-PD-1 immune checkpoint antibody in a lung cancer patient.
Jodai T; Yoshida C; Sato R; Kakiuchi Y; Sato N; Iyama S; Kimura T; Saruwatari K; Saeki S; Ichiyasu H; Fujii K; Tomita Y
Immun Inflamm Dis; 2019 Mar; 7(1):3-6. PubMed ID: 30461210
[TBL] [Abstract][Full Text] [Related]
20. Association of Tumor Mutational Burden With DNA Repair Mutations and Response to Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer.
Chae YK; Davis AA; Raparia K; Agte S; Pan A; Mohindra N; Villaflor V; Giles F
Clin Lung Cancer; 2019 Mar; 20(2):88-96.e6. PubMed ID: 30425022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
